Regulatory Approval/MiscellaneousFormycon and Fresenius Kabi receive European Commission approval for FYB202/Otulfi® (ustekinumab) for the treatment of serious inflammatory diseases 27.09.2024 / 09:00 ...
In a recent study, researchers conducted ... Immune Cell Regulator Discovery Could Lead to Treatments for Arthritis and Severe COVID Aug. 14, 2024 — The discovery of a new regulator affecting ...
Standard ALL treatment usually takes between 2 to 3 years. The maintenance phase takes up most of this time as it lasts 2 years. During the maintenance phase people often go back to work or college.